Nanobiotix H1 FY26 net loss widens to €34.3 million; revenue and other operating income drops to €5.6 million
Bitget2026/09/24 20:16- Nanobiotix first-half 2026 revenue and other operating income fell 78.95% to EUR 5.6 million.
- Net loss attributable to ordinary shareholders widened to EUR 34.3 million, or EUR 0.70 per share.
- R&D expenses slipped to EUR 12.7 million, while SG&A costs edged down to EUR 10.8 million.
- Cash and cash equivalents climbed to EUR 110.9 million at June 30, extending financial runway through 2029.
- Laurent Levy cited encouraging JNJ-1900 (NBTXR3) data across indications and a Phase 3 NANORAY-312 protocol amendment to enable an earlier final readout.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Crypto prices
More
